Clinical Trial Update: The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update investigating the efficacy and safety of rilzabrutinib in participants aged 10 to 65 with sickle cell disease; currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Rilzabrutinib (rilzabrutinib)

Snippet

Sponsor: Sanofi | Conditions: Sickle Cell Disease | Phase 3 | Status: RECRUITING